National Bank Financial downgraded shares of Theratechnologies (TSE:TH) from an outperform market weight rating to a sector perform market weight rating in a research report sent to investors on Thursday morning.

TH has been the subject of a number of other research reports. Stifel Nicolaus assumed coverage on shares of Theratechnologies in a report on Tuesday, May 14th. They issued a buy rating and a C$15.00 price objective for the company. Royal Bank of Canada set a $184.00 target price on shares of Jazz Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, July 3rd. Finally, Mackie reduced their price target on shares of Theratechnologies from C$8.15 to C$7.00 and set a hold rating on the stock in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. The company presently has an average rating of Buy and an average price target of C$9.56.

Shares of TSE TH opened at C$5.85 on Thursday. The stock has a market cap of $449.88 million and a price-to-earnings ratio of -92.86. The business has a fifty day moving average of C$6.75. The company has a debt-to-equity ratio of 159.35, a quick ratio of 2.09 and a current ratio of 2.69. Theratechnologies has a one year low of C$5.17 and a one year high of C$11.45.

Several hedge funds and other institutional investors have recently modified their holdings of TH. Virtu Financial LLC purchased a new stake in Theratechnologies during the 1st quarter worth about $96,000. Mesirow Financial Investment Management Inc. purchased a new stake in Theratechnologies in the 1st quarter valued at about $328,000. LLBH Private Wealth Management LLC purchased a new stake in shares of Theratechnologies during the 1st quarter worth about $1,735,000. Finally, Monarch Partners Asset Management LLC purchased a new stake in shares of Theratechnologies during the 1st quarter worth about $4,256,000.

Theratechnologies Company Profile

Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.

Further Reading: How are the companies in the S&P 500 selected?

Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.